<DOC>
	<DOCNO>NCT02210195</DOCNO>
	<brief_summary>The primary aim supplemental study provide POC test aprepitant treatment comorbid alcohol cannabis dependence . The data analysis plan specify parent grant likewise apply supplemental project test effect aprepitant vs placebo measure alcohol cannabis use protract withdrawal . The primary hypothesis subject treat aprepitant significantly less alcohol marijuana use subject treat placebo .</brief_summary>
	<brief_title>Pharmacological Treatment Comorbid Alcohol Marijuana Withdrawal Dependence</brief_title>
	<detailed_description>Consistent scope method parent grant , randomize , double-blind , placebo-controlled , parallel group , Phase II , single-site , 8-week clinical trial aprepitant 125 mg/d placebo . Participants 40 outpatient seek treatment concurrent alcohol cannabis dependence . All participant receive weekly protocol-specific counseling . Research assessments occur weekly treatment phase 8-week study . Post treatment follow-up assessment occur Weeks 9 12 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Males female 1870 year age Meets DSM IV criterion current alcohol cannabis dependence Seeking researchbased outpatient treatment alcohol cannabis dependence involve daily oral medication Negative BAC CIWA score &lt; 9 randomization Significant medical disorder use medication increase potential risk influence study outcomes Females pregnant , nurse sexually active childbearing potential refuse use effective , non hormonal method birth control study 4 week study termination• Treatment investigational drug previous month Prior treatment NK1 antagonists Participants treatment mandate legal authority• Inability understand and/or comply provision protocol consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cannabis Treatment</keyword>
	<keyword>Alcohol Treatment</keyword>
	<keyword>Alcohol-Related Disorders</keyword>
	<keyword>Cannabis-Related Disorders</keyword>
	<keyword>Substance-Related Disorders</keyword>
	<keyword>Emend</keyword>
	<keyword>NK1 receptor antagonist</keyword>
	<keyword>Alcohol</keyword>
	<keyword>Cannabis</keyword>
	<keyword>aprepitant</keyword>
</DOC>